Popular Searches:

    Using real-world evidence for label expansion: Use of palbociclib in male breast cancer patients

    Summary of: Bartlett CH, Mardekian J, Yu-Kite M, Cotter MJ, Kim S, Decembrino J, Snow T, Carson KR, Rockland JM, Kraus AL, Wilner KD, Oharu N, Schnell P, Lu D, Tursi J. Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET). Poster presented at: 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO); June, 2019; Chicago, IL.

    Our summary

    Real-world evidence helped provide data of the use of palbociclib in males with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Analysis of de-identified claims data and de-identified EHR-derived Flatiron data on men with HR+, HER2- metastatic breast cancer treated in combination with palbociclib in the real world supported the FDA’s expansion of the palbociclib approval, previously only approved in women, to include men with HR+, HER2- metastatic breast cancer.

    Interested in working with Flatiron data?

    Contact our Life Sciences Partnerships team to get started.

    arrow

    Sales CTA Form

    Why this matters

    The advent of CDK inhibitors such as palbociclib has dramatically changed the way breast cancer is treated. However, the original approvals did not include male patients, an extremely rare patient population. The traditional standards of prospective clinical evidence would be nearly impossible to meet in order to secure a regulatory approval for male patients with breast cancer. This study shows how rigorous deployment of RWE could fit into the clinical evidence paradigm, complementing clinical trials where needed, to ultimately bring valuable therapeutic advances to patients in need.

    Read the research

    Related articles